Bayer (BAYRY)
(Delayed Data from OTC)
$7.99 USD
-0.09 (-1.11%)
Updated Sep 20, 2024 03:59 PM ET
2-Buy of 5 2
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BAYRY 7.99 -0.09(-1.11%)
Will BAYRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAYRY
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
Other News for BAYRY
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Bayer (0P6S) Receives a Hold from Jefferies
Trinity Biotech provides update on CGM technology collaboration with Bayer
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study